An FDA panel supported data submitted by Genzyme General and partner BioMarin Pharmaceutical Inc. for Aldurazyme, an enzyme replacement therapy for the treatment of a rare degenerative disease, mucopolysaccharidosis-1 (MPS-1). (Bioworld Today)